Senseonics Inc. (SENS), a medical technology company, announced on Thursday the pricing of an underwritten public offering of 8 million shares of common stock at $5.00 per share. To certain investors, the company is offering pre-funded warrants to purchase up to 8 million shares of common stock at $4.99 per share.
Additionally, the company is offering underwriters an option to purchase up to 2.4 million shares at the public offering price.
The offering is expected to close on May 4, 2026. Gross proceeds from the offering are estimated at $80 million.
The company is currently developing Eversense, a continuous glucose monitoring (CGM) system for people with diabetes. This includes Eversense 365, and Eversense 3, and consists of sub-cutaneous sensors that communicates with a smart transmitter worn on the skin.
SENS is currently trading at $5.14, down 22.24%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.